Nonalcoholic Steatohepatitis Nash Epidemiology Forecast

DelveInsight's 'Nonalcoholic Steatohepatitis (NASH) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Nonalcoholic Steatohepatitis (NASH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Nonalcoholic Steatohepatitis (NASH) Understanding

The DelveInsight Nonalcoholic Steatohepatitis (NASH) epidemiology report gives a thorough understanding of the Nonalcoholic Steatohepatitis (NASH) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Nonalcoholic Steatohepatitis (NASH) in the US, Europe, and Japan. The report covers the detailed information of the Nonalcoholic Steatohepatitis (NASH) epidemiology scenario in seven major countries (US, EU5, and Japan).


Nonalcoholic Steatohepatitis (NASH) Epidemiology Perspective by DelveInsight

The Nonalcoholic Steatohepatitis (NASH) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Nonalcoholic Steatohepatitis (NASH) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Nonalcoholic Steatohepatitis (NASH) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Nonalcoholic Steatohepatitis (NASH) Detailed Epidemiology Segmentation

The Nonalcoholic Steatohepatitis (NASH) epidemiology covered in the report provides historical as well as forecasted Nonalcoholic Steatohepatitis (NASH) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Nonalcoholic Steatohepatitis (NASH) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Nonalcoholic Steatohepatitis (NASH) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Nonalcoholic Steatohepatitis (NASH) Epidemiology Report and Model provide an overview of the risk factors and global trends of Nonalcoholic Steatohepatitis (NASH) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Nonalcoholic Steatohepatitis (NASH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Nonalcoholic Steatohepatitis (NASH)
  • The report provides the segmentation of the Nonalcoholic Steatohepatitis (NASH) epidemiology


Report Highlights

  • 11-Year Forecast of Nonalcoholic Steatohepatitis (NASH) epidemiology
  • 7MM Coverage
  • Total Cases of Nonalcoholic Steatohepatitis (NASH)
  • Total Cases of Nonalcoholic Steatohepatitis (NASH) according to segmentation
  • Diagnosed cases of Nonalcoholic Steatohepatitis (NASH)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Nonalcoholic Steatohepatitis (NASH)?
  • What are the key findings pertaining to the Nonalcoholic Steatohepatitis (NASH) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Nonalcoholic Steatohepatitis (NASH) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Nonalcoholic Steatohepatitis (NASH)?
  • What are the currently available treatments of Nonalcoholic Steatohepatitis (NASH)?


Reasons to buy

  • The Nonalcoholic Steatohepatitis (NASH) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market
  • Quantify patient populations in the global Nonalcoholic Steatohepatitis (NASH) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Nonalcoholic Steatohepatitis (NASH) therapeutics in each of the markets covered
  • Understand the magnitude of Nonalcoholic Steatohepatitis (NASH) population by its epidemiology
  • The Nonalcoholic Steatohepatitis (NASH) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)

3. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Nonalcoholic Steatohepatitis (NASH) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Nonalcoholic Steatohepatitis (NASH) Treatment and Management

6.2. Nonalcoholic Steatohepatitis (NASH) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Nonalcoholic Steatohepatitis (NASH) Epidemiology in 7MM (2017-2030)

Table 2 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Nonalcoholic Steatohepatitis (NASH) Epidemiology in the United States (2017-2030)

Table 4 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Germany (2017-2030)

Table 6 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Nonalcoholic Steatohepatitis (NASH) Epidemiology in France (2017-2030)

Table 8 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Italy (2017-2030)

Table 10 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Spain (2017-2030)

Table 12 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Nonalcoholic Steatohepatitis (NASH) Epidemiology in the United Kingdom (2017-2030)

Table 14 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Japan (2017-2030)

Table 16 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Nonalcoholic Steatohepatitis (NASH) Epidemiology in 7MM (2017-2030)

Figure 2 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Nonalcoholic Steatohepatitis (NASH) Epidemiology in the United States (2017-2030)

Figure 4 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Germany (2017-2030)

Figure 6 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Nonalcoholic Steatohepatitis (NASH) Epidemiology in France (2017-2030)

Figure 8 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Italy (2017-2030)

Figure 10 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Spain (2017-2030)

Figure 12 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Nonalcoholic Steatohepatitis (NASH) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Nonalcoholic Steatohepatitis (NASH) Epidemiology in Japan (2017-2030)

Figure 16 Nonalcoholic Steatohepatitis (NASH) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Nonalcoholic Steatohepatitis (NASH)...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...
  • Nonalcoholic Steatohepatitis (NASH...

Forward to Friend

Need A Quote